Laws · federal-scheduling

Op-Ed Flags DEA Rescheduling Process as Source of Market Uncertainty

A Marijuana Moment op-ed argues DEA's handling of marijuana rescheduling has left state regulators, patients and licensed operators without a clear legal roadmap.

By Tomas Greer, State Policy ReporterPublished November 16, 20264 min read
A contemporary office building featuring a striking glass facade and lush surroundings.

A contemporary office building featuring a striking glass facade and lush surroundings.

A Marijuana Moment op-ed published Nov. 16, 2026 argues the DEA's approach to rescheduling marijuana under the Controlled Substances Act is creating deep uncertainty for state regulators, patients and licensed operators. The piece is commentary, not a rule, but it frames the compliance, tax and planning questions the agency has not resolved.

An op-ed, not a rule, puts the DEA's process under scrutiny

The Nov. 16 commentary in Marijuana Moment is opinion, and it doesn't change the legal status of marijuana. It does capture a planning problem that regulators and operators have raised for months.

Marijuana remains a Schedule I substance under 21 U.S.C. § 812. Any move to Schedule III would run through the DEA's administrative process. That process has produced more questions than answers.

The op-ed's central point, as framed in its headline, is that the agency's approach is generating uncertainty across three groups: regulators, patients and market operators. CannIntel has only the headline and publication details to go on. We haven't independently reviewed the full text, so this report doesn't attribute specific arguments, quotes or proposals to its author beyond that framing.

Why procedural ambiguity is a compliance problem

Rescheduling isn't a single event. It's a sequence of procedural steps, and each step carries its own legal risk. A proposed rule, public comment, possible hearing and a final rule are distinct milestones with different consequences for the people who must plan around them.

Federal rulemaking is governed by the Administrative Procedure Act, and a final scheduling action can be challenged in court. A rule that is proposed but not final binds no one. Neither does a rule that is final but stayed or litigated. Operators can't book tax savings on a document that might be vacated, and regulators can't rewrite state frameworks on one either.

That's the practical meaning of uncertainty here. It isn't abstract. It comes down to which date, if any, an operator can put in a financial model.

What changes for operators, and what does not

A Schedule III placement would not, by itself, legalize state-licensed marijuana businesses under federal law. Operators would still face the Controlled Substances Act's registration and distribution requirements, which were never designed around a retail cannabis market.

The most cited financial effect is on Internal Revenue Code Section 280E, which bars deductions for businesses trafficking in Schedule I and II substances. Whether and when 280E relief applies depends on the effective date and the final text of any rule. Tax counsel have long cautioned that the gap between a rule's announcement and its effective date matters as much as the schedule itself.

The op-ed's framing, paraphrased, is that the lack of a settled path leaves each stakeholder group planning against a different set of assumptions.

That mismatch is the real cost. A multi-state operator, a state regulator and a medical patient each read the same ambiguity differently, and none of them has a binding federal document to anchor to.

The regulator and patient lens

State regulators carry the immediate administrative burden, because state programs sit on top of an unresolved federal baseline. Agencies in states such as California and Ohio write testing, packaging and licensing rules that assume federal law stays put. A rescheduling action could force revisions. Regulators can't draft those revisions without knowing the final text.

Patients face a quieter version of the same problem. Medical access, insurance coverage and physician participation all hinge on federal classification, and a state can't resolve any of them alone. Whether a Schedule III designation would alter prescribing or research access depends on rule language that hasn't been finalized.

For full background on this story, see the CannIntel topic hub on DEA marijuana rescheduling.

None of this is a surprise. Commentary pieces like this one tend to surface when a regulatory timeline stalls and stakeholders run out of official documents to read.

The next signal to watch is any Federal Register notice or docket activity from the DEA. Until a dated, final action appears, regulators, patients and operators are planning against assumptions rather than a rule.

Full context

For complete background, history, and our ongoing coverage of this story:

Open the CannIntel topic hub →

Sources

DEA reschedulingSchedule III21 U.S.C. § 812Section 280Efederal cannabis policystate regulators
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.

Related from Laws

More from the newsroom